Epigenomics AG (ECX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Epigenomics AG (ECX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013864
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung BL Reflex assay, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.

Epigenomics AG (ECX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Epigenomics AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Epigenomics AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Epigenomics AG, Medical Equipment, Deal Details 11
Partnerships 11
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Announces Option Licensing Agreement With QIAGEN 15
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 16
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 17
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 18
Equity Offering 19
Epigenomics Raises USD6.5 Million in Private Placement of Shares 19
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 20
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 21
Epigenomics Raises USD5.3 Million in Private Placement of Shares 22
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 24
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 25
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 26
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 27
Debt Offering 28
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 28
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 29
Acquisition 30
Cathay Fortune International to Acquire Epigenomics 30
Epigenomics AG – Key Competitors 32
Epigenomics AG – Key Employees 33
Epigenomics AG – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 35
May 10, 2017: Epigenomics announces 2017 First Quarter Financial Results 36
Apr 26, 2017: Epigenomics Reports Results for Financial Year 2016 37
Nov 09, 2016: Epigenomics Announces 2016 Third Quarter and Nine Months Financial Results and Reports on Operational Highlights 38
Aug 10, 2016: Epigenomics Announces 2016 Second Quarter and Six Months Financial Results and Reports on Operational Highlights 40
May 23, 2016: Epigenomics Announces 2016 First Quarter Financial Results and Reports on Operational Highlights 41
Mar 18, 2016: Epigenomics Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016 42
Corporate Communications 44
Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 44
Jun 30, 2016: Supervisory Board of Epigenomics appoints Gregory Hamilton as Chief Executive Officer (CEO) 45
Product News 46
Apr 18, 2016: Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Epigenomics AG, Medical Equipment, Key Facts, 2016 2
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Epigenomics AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Epigenomics AG, Deals By Market, 2011 to YTD 2017 9
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Announces Option Licensing Agreement With QIAGEN 15
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 16
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 17
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 18
Epigenomics Raises USD6.5 Million in Private Placement of Shares 19
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 20
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 21
Epigenomics Raises USD5.3 Million in Private Placement of Shares 22
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 24
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 25
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 26
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 27
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 28
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 29
Cathay Fortune International to Acquire Epigenomics 30
Epigenomics AG, Key Competitors 32
Epigenomics AG, Key Employees 33
Epigenomics AG, Subsidiaries 34

★海外企業調査レポート[Epigenomics AG (ECX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quest Diagnostics Inc (DGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Quest Diagnostics Inc (Quest Diagnostics) is a provider of diagnostic information services to patients and physicians through a chain of laboratories and company-owned patient service centers. It offers comprehensive range of services including clinical testing with gene-based and other esot …
  • Jefferies Group LLC:企業の戦略・SWOT・財務分析
    Jefferies Group LLC - Strategy, SWOT and Corporate Finance Report Summary Jefferies Group LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • NeuroMetrix Inc (NURO):医療機器:M&Aディール及び事業提携情報
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • Aphios Corp-製薬・医療分野:企業M&A・提携分析
    Summary Aphios Corp (Aphios) is a biotechnology company that develops nanotechnology drug delivery platforms. The company provides technology platforms and enhanced therapeutics for the treatment of infectious diseases, cancers and central nervous system disorders. Its therapeutic products include Z …
  • Warner Media LLC.:企業の戦略・SWOT・財務情報
    Warner Media LLC. - Strategy, SWOT and Corporate Finance Report Summary Warner Media LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Kuwait And Middle East Financial Investment Company (K.S.C.P.) (KMEFIC):企業の財務・戦略的SWOT分析
    Kuwait And Middle East Financial Investment Company (K.S.C.P.) (KMEFIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view …
  • ConSynance Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary ConSynance Therapeutics Inc (ConSynance Therapeutics) is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company’s pipeline programs include CSTI-100, CSTI-200, and CSTI-300 among others. It develops pipeline programs fo …
  • H3 Biomedicine Inc-製薬・医療分野:企業M&A・提携分析
    Summary H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utiliz …
  • Cielo Wind Power, LP-エネルギー分野:企業M&A・提携分析
    Summary Cielo Wind Power, LP (Cielo Wind) is a wind power project development company. It designs, develops, owns and operates utility-grade wind power projects. The company provides a wide range of services including engineering, construction, operations and maintenance, land procurement, meteorolo …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma plc (Strongbridge) formerly Cortendo Plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic …
  • Genetic Signatures Ltd (GSS):医療機器:M&Aディール及び事業提携情報
    Summary Genetic Signatures Ltd (Genetic Signatures), formerly Human Genetic Signatures Pty Ltd, is a molecular diagnostics company. The company designs and manufactures real-time polymerase chain reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. It of …
  • MetaStat Inc (MTST):医療機器:M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Macquarie Group Ltd
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wilmar International Limited:企業の戦略・SWOT・財務情報
    Wilmar International Limited - Strategy, SWOT and Corporate Finance Report Summary Wilmar International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Audi AG (NSU):企業の財務・戦略的SWOT分析
    Audi AG (NSU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Aeon Co., Ltd.:企業の戦略・SWOT・財務分析
    Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Avery Dennison Corporation (AVY):医療機器:M&Aディール及び事業提携情報
    Summary Avery Dennison Corporation (Avery Dennison) is a labeling and packaging materials and solutions provider. The company produces pressure-sensitive materials, tags, labels, tickets, and other converted products. It also manufactures and sells fasteners, tickets, tags, RFID inlays and tags, and …
  • Delaware Electric Cooperative Inc:企業の戦略的SWOT分析
    Delaware Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Ivy Cosmetics Corporation:企業の戦略・SWOT・財務情報
    Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report Summary Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mikros Systems Corporation:企業の戦略・SWOT・財務情報
    Mikros Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Mikros Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆